The present disclosure pertains to medical devices, and methods for manufacturing medical devices. More particularly, the present disclosure pertains to medical devices and methods for mapping and/or ablating cardiac tissue.
A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include guidewires, catheters, and the like. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices as well as alternative methods for manufacturing and using medical devices.
This disclosure provides design, material, manufacturing method, and use alternatives for medical devices. An example method of mapping electrical activity of a heart comprises sensing a plurality of signals with a plurality of electrodes positioned within the heart, separating the plurality of signals into a first group of signals and a second group of signals, and generating a data set that includes at least one known data point and one or more unknown data points, wherein the at least one known data point is generated based on the first group of signals.
Alternatively or additionally to any of the embodiments above, wherein the one or more unknown data points are generated based on the second group of signals.
Alternatively or additionally to any of the embodiments above, wherein the processing comprises one or more of the following: performing a wavelet transform on the plurality of signals, rectifying the plurality of signals, low-pass filtering the plurality of signals.
Alternatively or additionally to any of the embodiments above, wherein separating the plurality of signals into a first group of signals and a second group of signals comprises performing statistical analysis on the plurality of signals.
Alternatively or additionally to any of the embodiments above, wherein separating the plurality signals into a first group of signals and a second group of signals further comprises clustering the results of the statistical analysis, wherein the clustering produces the first group of signals and the second group of signals.
Alternatively or additionally to any of the embodiments above, wherein clustering the results of the statistical analysis comprises one of: performing a distribution-based clustering of the results of the statistical analysis, or performing a density-based clustering of the results of the statistical analysis.
Alternatively or additionally to any of the embodiments above, wherein performing a distribution-based clustering of the results of the statistical analysis comprises performing a Gaussian mixture model analysis of the results of the statistical analysis.
Alternatively or additionally to any of the embodiments above, wherein the statistical analysis comprises principal component analysis.
Another example method of identifying activation times in a plurality of signals may comprise collecting a plurality of cardiac electrical signals with a plurality of electrodes disposed within a heart, wherein each electrode collects a single cardiac electrical signal, identifying a characteristic signal from the plurality of collected cardiac electrical signals, identifying timing of one or more activation events in the characteristic signal, processing the plurality of cardiac electrical signals, clustering the plurality of cardiac electrical signals into a first cluster of signals and a second cluster of signals, wherein the first cluster of signals includes the characteristic signal, and determining an activation time for each of the cardiac electrical signals in the first cluster of signals.
Alternatively or additionally to any of the embodiments above, wherein processing the plurality of signals comprises one or more of the following: performing a wavelet transform on the plurality of signals, rectifying the plurality of signals, and low-pass filtering the plurality of signals.
Alternatively or additionally to any of the embodiments above, wherein clustering the plurality of cardiac electrical signals into a first cluster of signals and a second cluster of signals comprises: performing statistical analysis on the plurality of signals, and performing a density-based clustering of the results of the statistical analysis, wherein the results of the density-based clustering comprises the first cluster of signals and the second cluster of signals.
Alternatively or additionally to any of the embodiments above, wherein: performing statistical analysis comprises performing principal component analysis, and performing the density-based clustering comprises performing a Gaussian mixture model analysis.
Alternatively or additionally to any of the embodiments above, wherein determining activation times for each of the cardiac electrical signals in the first cluster of signals comprises: determining an activation time for the characteristic signal based on the identified timing of the one or more activation events in the characteristic signal, identifying one or more peaks in each of the other cardiac electrical signals in the first cluster of signals, identifying timings of each of the identified one or more peaks in each of the other cardiac electrical signals, and determining activation times for each of the other cardiac electrical signals based on the identified timings of the identified one or more peaks.
Alternatively or additionally to any of the embodiments above, wherein determining activation times for each of the other cardiac electrical signals based on the identified one or more peaks further comprises: removing one or more of the identified one or more peaks in each of the other cardiac electrical signals based on the identified timings of the one or more activation events in the characteristic signal, and determining activation times for each of the other cardiac electrical signals based on the remaining identified one or more peaks.
Alternatively or additionally to any of the embodiments above, may further comprise wherein determining activation times in each of the cardiac electrical signals in the first cluster of signals comprises: identifying a timing of a fiducial point in each of the signals in the first cluster of signals, determining a difference in timing between the fiducial point and one or more of the activation events in the characteristic signal, identifying timings of one or more peaks in the other cardiac electrical signals in the first cluster of signals, determining a difference in timing between the fiducial point and one or more of the identified one or more peaks in the other cardiac electrical signals in the first cluster of signals, and determining activation times based on the determined differences.
An example medical system for mapping electrical activity of a heart may comprise a catheter shaft, a plurality of electrodes coupled to the catheter shaft, a processor coupled to the catheter shaft, wherein the processor is configured to: collect a plurality of cardiac electrical signals, separating the plurality of cardiac electrical signals into a first group of signals and a second group of signals, and generating a data set that includes at least one known data point and one or more unknown data points.
Alternatively or additionally to any of the embodiments above, wherein generating a data set that includes at least one known data point and one or more unknown data points comprises: generating a known data point for each signal in the first group of signals, and generating an unknown data point for each signal in the second group of signals.
Alternatively or additionally to any of the embodiments above, further comprising identifying a characteristic signal, and identifying timing of activation events in the characteristic signal, wherein the first group of signals includes the characteristic signal.
Alternatively or additionally to any of the embodiments above, further comprising determining an activation time for the characteristic signal based on the identified timing of the activation events in the characteristic signal, identifying one or more peaks in each of the other cardiac electrical signals in the first group of signals, identifying timing of each of the identified one or more peaks in each of the other cardiac electrical signals, and determining activation times for each of the other cardiac electrical signals based on the identified timing of the identified one or more peaks.
Alternatively or additionally to any of the embodiments above, further comprising wherein the at least one known data point and the one or more unknown data points comprise activation times.
The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.
The disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:
While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
It is noted that references in the specification to “an example”, “some examples”, “other examples”, etc., indicate that the example described may include one or more particular features, structures, and/or characteristics. However, such recitations do not necessarily mean that all examples include the particular features, structures, and/or characteristics. Additionally, when particular features, structures, and/or characteristics are described in connection with one example, it should be understood that such features, structures, and/or characteristics may also be used connection with other examples whether or not explicitly described unless clearly stated to the contrary. Also, when particular features, structures, and/or characteristics are described in connection with one example, it is implicit that other examples may include less than all of the disclosed features, structures, and/or characteristics in all combinations.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
Mapping the electrophysiology of heart rhythm disorders often involves the introduction of a constellation catheter or other mapping/sensing device having a plurality of electrodes and/or sensors (e.g., CONSTELLATION®, commercially available from Boston Scientific) into a cardiac chamber. The sensors, for example electrodes, detect cardiac electrical activity at sensor locations. It may be desirable to have the cardiac electrical activity processed into electrogram signals that accurately represent cellular excitation through cardiac tissue relative to the sensor locations. A processing system may then analyze and output the signal to a display device. Further, the processing system may output the signal as an activation or vector field map. A user, such as a physician, may use the activation or vector field map to perform a diagnostic procedure.
Some example catheters may include sixty-four or more electrodes which each detect cardiac electrical activity. Accordingly, the processing system may process each of the sixty-four or more detected cardiac electrical activity signals into electrogram signals. In some examples, a user may then input information for each of the sixty-four or more electrogram signals which the processing system uses in determining pieces of data to populate an activation map. This inputting of information for such a high number of electrogram signals can result in lengthy procedure times. The methods and systems disclosed herein are designed to reduce the amount of information a user needs to input for the processing system to determine pieces of data to populate an activation map. For example, some of the methods disclosed herein may reduce the number of electrogram signals for which a user needs to input information or suggest information to a user for review for at least some of the electrogram signals. Other methods and medical devices are also disclosed.
System 10 includes mapping probe 14 and ablation probe 16. Each probe 14/16 may be separately introduced into the selected heart region 12 through a vein or artery (e.g., the femoral vein or artery) using a suitable percutaneous access technique. Alternatively, mapping probe 14 and ablation probe 16 can be assembled in an integrated structure for simultaneous introduction and deployment in the heart region 12.
Mapping probe 14 may include flexible catheter body 18. The distal end of catheter body 18 carries three-dimensional multiple electrode structure 20. In the illustrated embodiment, structure 20 takes the form of a basket defining an open interior space 22 (see
In some examples, electrodes 24 may be configured to detect activation signals of the intrinsic physiological activity within the anatomical structure. For example, intrinsic cardiac electrical activity may comprise repeating or semi-repeating waves of electrical activity with relatively large spikes in activity at the beginning of activation events. Electrodes 24 may sense such activation events and the times at which such activation events occur. Generally, electrodes 24 may sense activation events at different times as an electrical activity wave propagates through the heart. For instance, an electrical wave may begin near a first group of electrodes 24, which may sense an activation event at relatively the same time or within a relatively small window of time. As the electrical wave propagates through the heart, a second group of electrodes 24 may sense the activation even of the electrical wave at times later than the first group of electrodes 24.
Electrodes 24 are electrically coupled to processing system 32. A signal wire (not shown) may be electrically coupled to each electrode 24 on structure 20. The signal wires may extend through body 18 of probe 14 and electrically couple each electrode 24 to an input of processing system 32. Electrodes 24 sense cardiac electrical activity in the anatomical region, e.g., myocardial tissue, adjacent to their physical location within the heart. The sensed cardiac electrical activity (e.g., electrical signals generated by the heart which may include activation signals) may be processed by processing system 32 to assist a user, for example a physician, by generating an anatomical map (e.g., a vector field map, an activation time map) to identify one or more sites within the heart appropriate for a diagnostic and/or treatment procedure, such as an ablation procedure. For example, processing system 32 may identify a near-field signal component (e.g., activation signals originating from cellular tissue adjacent to mapping electrodes 24) or an obstructive far-field signal component (e.g., activation signals originating from non-adjacent tissue). In such examples where structure 20 is disposed in an atrium of the heart, as in
Processing system 32 may include dedicated circuitry (e.g., discrete logic elements and one or more microcontrollers; application-specific integrated circuits (ASICs); or specially configured programmable devices, such as, for example, programmable logic devices (PLDs) or field programmable gate arrays (FPGAs)) for receiving and/or processing the acquired cardiac electrical activity. In some examples, processing system 32 includes a general purpose microprocessor and/or a specialized microprocessor (e.g., a digital signal processor, or DSP, which may be optimized for processing activation signals) that executes instructions to receive, analyze and display information associated with the received cardiac electrical activity. In such examples, processing system 32 can include program instructions, which when executed, perform part of the signal processing. Program instructions can include, for example, firmware, microcode or application code that is executed by microprocessors or microcontrollers. The above-mentioned implementations are merely exemplary, and the reader will appreciate that processing system 32 can take any suitable form for receiving electrical signals and processing the received electrical signals.
In some examples, processing system 32 may be configured to measure the sensed cardiac electrical activity in the myocardial tissue adjacent to electrodes 24. For example, processing system 32 may be configured to detect cardiac electrical activity associated with a dominant rotor or divergent activation pattern in the anatomical feature being mapped. Dominant rotors and/or divergent activation patterns may have a role in the initiation and maintenance of atrial fibrillation, and ablation of the rotor path, rotor core, and/or divergent foci may be effective in terminating the atrial fibrillation. Processing system 32 processes the sensed cardiac electrical activity to generate a display of relevant characteristics, such as an isochronal map, activation time map, action potential duration (APD) map, a vector field map, a contour map, a reliability map, an electrogram, a cardiac action potential and the like. The relevant characteristics may assist a user to identify a site suitable for ablation therapy.
Ablation probe 16 includes flexible catheter body 34 that carries one or more ablation electrodes 36. The one or more ablation electrodes 36 are electrically connected to radio frequency (RF) generator 37 that is configured to deliver ablation energy to the one or more ablation electrodes 36. Ablation probe 16 may be movable with respect to the anatomical feature to be treated, as well as structure 20. Ablation probe 16 may be positionable between or adjacent to electrodes 24 of structure 20 as the one or more ablation electrodes 36 are positioned with respect to the tissue to be treated.
Processing system 32 may output data to a suitable device, for example display device 40, which may display relevant information for a user. In some examples, device 40 is a CRT, LED, or other type of display, or a printer. Device 40 presents the relevant characteristics in a format useful to the user. In addition, processing system 32 may generate position-identifying output for display on device 40 that aids the user in guiding ablation electrode(s) 36 into contact with tissue at the site identified for ablation.
The illustrated three-dimensional multiple electrode structure 20 comprises base member 41 and end cap 42 between which flexible splines 44 generally extend in a circumferentially spaced relationship. As discussed herein, structure 20 may take the form of a basket defining an open interior space 22. In some examples, the splines 44 are made of a resilient inert material, such as Nitinol, other metals, silicone rubber, suitable polymers, or the like and are connected between base member 41 and end cap 42 in a resilient, pretensioned condition, to bend and conform to the tissue surface they contact. In the example illustrated in
Slidable sheath 50 may be movable along the major axis of catheter body 18. Moving sheath 50 distally relative to catheter body 18 may cause sheath 50 to move over structure 20, thereby collapsing structure 20 into a compact, low profile condition suitable for introduction into and/or removal from an interior space of an anatomical structure, such as, for example, the heart. In contrast, moving sheath 50 proximally relative to the catheter body may expose structure 20, allowing structure 20 to elastically expand and assume the pretensed position illustrated in
A signal wire (not shown) may be electrically coupled to each mapping electrode 24. The signal wires may extend through body 18 of mapping catheter 20 (or otherwise through and/or along body 18) into handle 54, in which they are coupled to external connector 56, which may be a multiple pin connector. Connector 56 electrically couples mapping electrodes 24 to processing system 32. It should be understood that these descriptions are just examples. Some addition details regarding these and other example mapping systems and methods for processing signals generated by a mapping catheter can be found in U.S. Pat. Nos. 6,070,094, 6,233,491, and 6,735,465, the disclosures of which are hereby expressly incorporated herein by reference.
To illustrate the operation of system 10,
After basket structure 20 is positioned adjacent to the anatomical structure to be treated (e.g. left atrium, left ventricle, right atrium, or right ventricle of the heart), processing system 32 is configured to record the cardiac electrical activity from each electrode 24 channel, and the cardiac electrical activity is related to physiological activity of the adjacent anatomical structure. For instance, cardiac electrical activity may include activation signals which may indicate an onset of physiological activity, such as a contraction of the heart. Electrodes 24 sense such cardiac electrical activity which includes activation signals. The cardiac electrical activity of physiological activity may be sensed in response to intrinsic physiological activity (e.g. intrinsically generated electrical signals) or based on a predetermined pacing protocol instituted by at least one of the plurality of electrodes 24 (e.g. delivered electrical signals delivered by a pacing device).
The arrangement, size, spacing and location of electrodes along a constellation catheter or other mapping/sensing device, in combination with the specific geometry of the targeted anatomical structure, may contribute to the ability (or inability) of electrodes 24 to sense, measure, collect and transmit electrical activity of cellular tissue. As stated, because splines 44 of a mapping catheter, constellation catheter or other similar sensing device are bendable, they may conform to a specific anatomical region in a variety of shapes and/or configurations. Further, at any given position in the anatomical region, structure 20 may be manipulated such that one or more splines 44 may not contact adjacent cellular tissue. For example, splines 44 may twist, bend, or lie atop one another, thereby separating splines 44 from nearby cellular tissue. Additionally, because electrodes 24 are disposed on one or more of splines 44, they also may not maintain contact with adjacent cellular tissue. Electrodes 24 that do not maintain contact with cellular tissue may be incapable of sensing, detecting, measuring, collecting and/or transmitting electrical activity information. Further, because electrodes 24 may be incapable of sensing, detecting, measuring, collecting and/or transmitting electrical activity information, processing system 32 may be incapable of accurately displaying diagnostic information. For example, some necessary information may be missing and/or displayed inaccurately.
In addition to that stated above, electrodes 24 may not be in contact with adjacent cellular tissue for other reasons. For example, manipulation of mapping catheter 14 may result in movement of electrodes 24, thereby creating poor electrode-to-tissue contact. Further, electrodes 24 may be positioned adjacent fibrous, dead or functionally refractory tissue. Electrodes 24 positioned adjacent fibrous, dead or functionally refractory tissue may not be able to sense changes in electrical potential because fibrous, dead or functionally refractory tissue may be incapable of depolarizing and/or responding to changes in electrical potential. Finally, far-field ventricular events and electrical line noise may distort measurement of tissue activity.
However, electrodes 24 that contact healthy, responsive cellular tissue may sense cardiac electrical activity such as a change in the voltage potential of a propagating cellular activation wavefront. Further, in a normal functioning heart, electrical discharge of the myocardial cells may occur in a systematic, linear fashion. Therefore, detection of non-linear propagation of the cellular excitation wavefront may be indicative of cellular firing in an abnormal fashion. For example, cellular firing in a rotating pattern may indicate the presence of dominant rotors and/or divergent activation patterns. Further, because the presence of the abnormal cellular firing may occur over localized target tissue regions, it is possible that electrical activity may change form, strength or direction when propagating around, within, among or adjacent to diseased or abnormal cellular tissue. Identification of these localized areas of diseased or abnormal tissue may provide a user with a location for which to perform a therapeutic and/or diagnostic procedure. For example, identification of an area including reentrant or rotor currents may be indicative of an area of diseased or abnormal cellular tissue. The diseased or abnormal cellular tissue may be targeted for an ablative procedure. An activation time map may be used to identify areas of circular, adherent, rotor or other abnormal cellular excitation wavefront propagation.
As described previously, in order to generate an activation time map, processing system may need to receive input from a user. For example, after sensing cardiac electrical activity at each electrode 24, processing system 32 may display the sensed cardiac electrical activity at display 40 as an electrogram. A user may then input information associated with each electrogram, and processing system 32 may use this input information to generate the activation time map. However, requiring a user to input information for each electrogram may be time consuming. Accordingly, one or more techniques described herein may reduce the number of electrograms for which processing system 32 needs a user to input information, and/or generate suggested input information.
In some examples, after collecting cardiac electrical activity sensed by electrodes 24, processing system 32 may generate a number of electrograms based on the sensed cardiac electrical activity equal to the number of electrodes of the system. Processing system may additionally display the generated electrograms, for example at display device 40. In some examples, the electrograms may simply be the raw sensed cardiac electrical activity. Processing system 32 may display each electrogram in a single graphical display, with all of the electrograms overlapping. Graph 400 in
In at least some examples, processing system 32 may identify a characteristic signal. A characteristic signal may be one of the electrograms which display characteristics of a normal electrogram, e.g. a series of obvious repeating or semi-repeating peaks and valleys. Such features may indicate that the electrode associated with the characteristic signal is in good electrical contact with the tissue. Processing system 32 may identify a characteristic signal by comparing each electrogram to a reference electrogram and generating a difference score, for example using one or more statistical techniques for indicating how similar each electrogram is to the reference electrogram. Processing system 32 may identify the electrogram with the highest score—that is, the most similar to the reference electrogram—as the characteristic signal. In other examples, processing system may use other techniques for identifying a characteristic electrogram. In still other examples, a user may select one of the electrograms as the characteristic signal. For example, processing system 32 may display each electrogram, and the user may select one of the displayed electrogram at display device 40 using a peripheral input device, e.g. a keyboard or mouse, or through touch input if display device 40 is a touch-sensitive display device. Alternatively, processing system 32 may identify one of the electrograms as an initial characteristic signal and may display the initial characteristic signal at display device 40. A user may then enter input either confirming the initial characteristic signal as the characteristic signal or selecting a different electrogram as the characteristic signal.
After identifying or determining a characteristic signal, processing system 32 may identify activation events and timings of any identified activation events in the characteristic signal. For example, processing system 32 may determine a derivative of the characteristic signal and identify locations within the derivative of the characteristic signal that are less than a predetermined threshold as activation events. In other examples, processing system 32 may user other techniques for identifying activation events in the characteristic signal. For instance, processing system 32 may employ a peak finding algorithm and determine that any identified peaks are activation events. In other examples, processing system 32 may display the characteristic signal at display device 40 and a user may select one or more locations in the characteristic signal as activation events. In still other examples, processing system 32 may identify one or more activation events and display the characteristic signal and determined activation events at display device 40. A user may modify the activation events identified by processing system 32, for example by removing identified activation events, adding activation events, and/or moving identified activation events. In any case, processing system 32 may additionally record the timings of the identified activation events.
Processing system 32 may additionally process each of the electrograms, as depicted in
In some examples, processing system 32 may additionally rectify example electrogram 606.
In additional examples, processing system 32 may further generate a power envelope of example electrogram 610. For example, processing system 32 may perform a low-pass filtering of example electrogram 610. In other examples, processing system 32 may utilize other techniques for generating a power envelope.
Although the above description described a technique for processing electrograms using multiple signal processing techniques, in other examples, only one or two of the processing techniques may be used. For example, processing the electrograms may only consist of performing a wavelet transform on the electrogram. In other examples, the processing may only consist of rectification. In still other examples, the processing may only consist of generating a power envelope. In yet other examples, any combination of two of these processes may be combined to perform processing on the electrogram. It is also noted that these processing techniques should not be viewed as limiting. In other examples, processing system 32 may use other and/or additional signal processing techniques to process the electrogram. Additionally, the above described process has been described with respect to a single electrogram, however, in practice, processing system 32 may perform similar processing techniques on each of the electrograms generated from each electrode 24.
After processing each of the electrograms, processing system 32 may additionally perform a statistical analysis on all of the processed electrograms. In some examples, processing system 32 may perform a cross correlation analysis between the characteristic signal and the processed electrograms. In other examples, processing system 32 may perform a Linear Discriminant Analysis on the processed electrograms. In at least some examples, processing system 32 may perform a principal component analysis on the processed electrograms.
Once processing system 32 has completed the statistical transformations of the processed electrograms, processing system 32 may cluster the results of the statistical transform. For example, processing system 32 may separate the results into multiple separate groups or clusters. In general, this clustering processing may identify groups of electrograms which are similar to one another, or on the basis of certain features within each electrogram. In some examples, processing system 32 may perform a density-based clustering technique in order to group or cluster the results of the statistical transform. In other examples, processing system 32 may perform a distribution-based clustering technique in order to group or cluster the results of the statistical transform. More specifically, in some examples where processing system 32 uses a distribution-based clustering technique, processing system 32 may perform a Gaussian mixture model (GMM) analysis on the results of the statistical transform. In at least some examples, the GMM analysis may be a two-dimensional analysis, and the results of the GMM analysis may be two separate groups or clusters of electrograms.
In some examples, the clustering process may produce more than two groups or clusters of electrograms. For example, in a GMM analysis, a user may select a specific number of groups or clusters as output of the GMM analysis. Accordingly, in examples where a user selects three groups or clusters, the output of the GMM analysis is three groups or clusters. However, in other examples, a user may select any number of groups or clusters. Selecting more than two groups or clusters may be advantageous in situations where the results of the statistical processing do not produce clear distinctions between electrograms.
In any event, one of the groups of electrograms contains the characteristic signal. In the example of
In some examples, performing a clustering process may begin with one or more estimated or guessed parameters, and different parameters may produce different results. For example, using a first set of parameters may end in a result that is a local minimum. Using a second set of parameters may also end in a result that is a local minimum, but the local minimum is a lower minimum that the local minimum using the first set of parameters. Accordingly, in order to determine a global minimum, that is a local minimum that is lowest of all local minimum, processing system 32 may perform the clustering process multiple times. In some examples, processing system 32 may perform the clustering process 25, 40, 50, or any other suitable number of times. Processing system 32 may then use the results with the lowest overall local minimum as the results of the clustering process—e.g. the groupings resulting from the clustering process resulting in the lowest overall local minimum.
In other examples, a user may not identify a characteristic signal. In such examples, processing system 32 may determine which group or cluster of electrograms is the “first group” and which group(s) or cluster(s) are the “second group.” For instance, after performing a statistical analysis, such as principal component analysis or other appropriate statistical processing techniques, processing system 32 may further test electrogram characteristics of each group. For example, processing system 32 may perform an organizational index calculation on the fast-fourier transform (FFT) of each electrogram within each group or cluster. Then, processing system 32 may determine the group or cluster which shows the greatest amount of organization in the FFTs of the electrograms as the “first group” and all of the other groups as part of the “second group.”
Once processing system 32 has separated the electrograms into at least a first and a second group, processing system 32 may additionally determine activation times for populating an activation time map. In some examples, processing system 32 may determine an activation time from the characteristic signal in a slightly different manner from the other electrograms in the first group. For example, processing system 32 already has stored in memory timings of activation events for the characteristic signal. Processing system may then identify one or more fiducial points in the characteristic signal. For example, one of the electrograms may be a reference electrogram. The reference electrogram may additionally have identified activation events and activation event timings associated with the activation events. Processing system 32 may identify one or more fiducial points in the characteristic signal with the same timings as the identified activation events in the reference electrogram. In other examples, processing system 32 may identify one or more particular features of the characteristic signal as fiducial points, such as the first data point of the characteristic signal. In examples where processing system 32 determines multiple fiducial points in the characteristic signal, processing system 32 may determine set data points as fiducial points, for example, every 10th, 50th, 100th, or the like data points may be fiducial points. Processing system 32 additionally determines the timings of the fiducial points within the characteristic signal.
In any event, processing system 32 may determine an activation time from the timings of the activation events and the fiducial points. For example, processing system 32 may determine a difference in timings between a fiducial point and an activation event, with the difference being the activation time for the characteristic signal. In other examples, processing system may determine multiple differences in times between fiducial points and activation times, with the average of the differences being the activation time for the characteristic signal. Processing system 32 may store such a determined activation time in memory.
As described above, processing system 32 may determine activation times for the other electrograms in the first group differently than for the characteristic signal. For example, none of the other electrograms have associated activation events and timings of activation events. Processing system 32 may begin by determining one or more activation events in the other electrograms. One technique processing system 32 may employ is to use a peak-finding algorithm to identify activation events in the other electrograms.
In order to reduce the number of identified peaks to peaks that only represent activation events, processing system 32 may compare the timings of the activation events in the characteristic signal to the timings of the peaks in the other electrograms. As described above, at the beginning of a physiological event, an electrical wave may propagate through the tissue adjacent to the electrodes. As this wave propagates through the tissue, each electrode may sense this wave, albeit at slightly different times. Accordingly, each electrodes may sense an activation event, but with slight differences in timing. Since activation events are already associated with the characteristic signal, the peaks in the other electrograms which identify activation events occur relatively closely in time to the timings of the activation events in the characteristic signal. Accordingly, processing system 32 may remove peaks identified in the other electrograms that fall outside of a time window defined around the timing of each activation event in the characteristic signal.
In some examples, multiple identified peaks may fall within an activation window 1010 (not shown in
The above process for identifying activation events in the other electrograms is just one example. In other examples, processing system 32 may use other techniques for identifying activation events in the other electrograms. For example, processing system 32 may determine a derivative of the characteristic signal and identify locations within the derivative of the characteristic signal that are less than a predetermined threshold as activation events. Processing system 32 may additionally use other techniques for determining activation events in the other electrograms.
After removing peaks in the other electrograms, or otherwise determining activation events in the other electrograms, processing system 32 may display each electrogram in the first group of electrograms at display device 40, including the determined activation events and activation event timings. In some of these examples, a user may modify the determined activation events. For example, a user may add activation events, remove determined activation events, or move determined activation events for each of the other electrograms in the first group. Processing system 32 may then store the activation events and activation event timings for each of the electrograms in the first group in memory.
Processing system 32 may then determine activation times for each of the other electrograms. For example, processing system 32 identify one or more fiducial points in each of the other electrograms. The fiducial point or points may be the same fiducial point or points as the fiducial points in the characteristic signal. For example, the timing of the fiducial point or points in the other electrograms may be the same as the timing of the fiducial point or points in the characteristic signal. Processing system 32 may then determine a difference in times between a fiducial point and an activation event for each of the other electrograms. This difference in timing is the activation time. In other examples, processing system may determine multiple differences in times between fiducial points and activation times for each of the other electrograms, with the average of the differences being the activation time. Processing system 32 may store such determined activation times in memory.
Processing system 32 may then display each of the electrograms in the second group of electrograms at display device 40. Processing system 32 may further receive input indicating activation events and activation event timings for each of the electrograms in the second group of electrograms. For example, a user may view one of the displayed electrograms and input information indicating an activation event. In some examples, the user may select a point on the electrogram with a peripheral input device, or using touch input if display device 40 is a touch-sensitive display, where the selected point represents an activation event. Processing system 32 may then determine an associated activation event timing for each received input indicating an activation event. Processing system 32 may additionally determine activation times for each of the electrograms in the second group in a similar manner as that described with respect to the characteristic signal—e.g. using one or more fiducial points and determining a difference or differences in timings of the fiducial point or points and activation events.
In this manner, processing system 32 may determine activation times for each of the electrograms in both the first and second groups of electrograms. Processing system may further populate an activation time map with these determined activation times and display the activation map at a display device, such as display device 40.
Space 1102 on map 1100 represents a known data point, e.g. a known activation time. Each of the spaces filled in with a value represent known data points. As described previously, in some examples, a known data point may be generated from each electrogram in the first group of electrograms. Accordingly, each filled in space represents one of the electrograms in the first group of electrograms, which is associated with the electrode labeled with a reference number the same as the combination of the row and column of the space.
In some examples, even after receiving input from a user, processing system 32 may not be able to determine activation times for one or more of the electrograms in the second group of electrograms. For example, a user may not be able to identify any activation events in one or more of the electrograms in the second group of electrograms and thus may not input any activation events to processing system 32. One reason may be that the electrode that sensed the cardiac electrical activity was not in good electrical contact with the tissue and therefore did not sense the propagating wave. Accordingly, the electrogram based off of the sensed cardiac electrical activity may not include any features that a user may identify as activation events. In such instances, processing system 32 may populate activation map 1100 with a symbol indicating an absence of an activation time for that electrode. In the example of
In some examples, processing system 32 may modify activation map 1100 in a number of different ways for display on display device 40. For example, processing system 32 may assign a unique, differentiating color to each space in table 1100. In some examples, the specific color is assigned based on the value of the activation time in the space. The color map may help a clinician identify the propagation direction of cellular firing. Activation map 1100 may display an activation time or color for known signals and not display an activation time or color for unknown and/or missing activation time data. The use of color to differentiate activation times is just an example. It is contemplated that other means may be used to differentiate activation times. For example, texture, symbols, numbers, or the like may be used as differentiating characteristics.
In order to maximize the utility of activation map 1100, it may be desirable to populate unknown activation times. Therefore, in some embodiments it may be desirable to interpolate activation times for missing signal data and populate and/or fill in the activation time map 1100 accordingly. Processing system 32 may perform any of the techniques disclosed in “MEDICAL DEVICES FOR MAPPING CARDIAC TISSUE,” a provisional patent application filed on Jan. 13, 2014, No. 61/926,737, which is hereby incorporated by reference in its entirety, for assigning values to the missing data.
In some examples, a catheter device, for instance catheter system 10, may include electrodes 24 which are disposed within a heart. System 10 may be configured to sense a plurality of signals with a plurality of electrodes positioned within the heart, as shown at 1202. System 10 may additionally separate the plurality of signals into a first group of signals and a second group of signals, as shown at 1204. For example, system 10 may utilize one or more signal processing, statistical, and/or clustering techniques to separate the plurality of signals in the first group of signals and the second group of signals. System 10 may additionally generate a data set that includes at least one known data point and one or more unknown data points, wherein the at least one known data point is generated based on the first group of signals, as shown at 1206. In some examples, the data points may be activation times.
In some examples, a catheter device, for instance catheter system 10, may include electrodes 24 which are disposed within a heart. System 10 may be configured to collect a plurality of cardiac electrical signals with a plurality of electrodes disposed within a heart, wherein each electrode collects a single cardiac electrical signal, as shown at 1302. System 10 may further be configured to identify a characteristic signal from the plurality of collected cardiac electrical signals, as shown at 1304. In some examples, system 10 may automatically identify a characteristic signal. In other examples, system 10 may receive input identifying a characteristic signal. System 10 may then identify timing of one or more activation events in the characteristic signal, as shown at 1306. Again, in some examples system 10 may determine the one or more activation events automatically. In other examples, system 10 may receive input indicating the one or more activation events.
System 10 may further process the plurality of cardiac electrical signals, as shown at 1308. For example, system 10 may perform one or more signal processing techniques on the plurality of cardiac electrical signals. Some example signal processing techniques include wavelet transforms, rectification, and filtering. System 10 may then cluster the plurality of cardiac electrical signals into a first cluster of signals and a second cluster of signals, wherein the first cluster of signals includes the characteristic signal, as shown at 1310. For example, system 10 may utilize one or more clustering techniques, such as density-based clustering techniques and/or distribution-based clustering techniques. Ultimately, system 10 may determine an activation time for each of the cardiac electrical signals in the first cluster of signals, as shown at 1312.
This application claims priority under 35 U.S.C. §119 to U.S. Provisional Application Ser. No. 61/951,266, filed Mar. 11, 2014, the entirety of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4433380 | Abele et al. | Feb 1984 | A |
4690152 | Juncosa | Sep 1987 | A |
5254088 | Lundquist et al. | Oct 1993 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5485849 | Panescu et al. | Jan 1996 | A |
5487391 | Panescu | Jan 1996 | A |
5494042 | Panescu et al. | Feb 1996 | A |
5527292 | Adams et al. | Jun 1996 | A |
5546940 | Panescu et al. | Aug 1996 | A |
5577509 | Panescu et al. | Nov 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5595183 | Swanson et al. | Jan 1997 | A |
5598848 | Swanson et al. | Feb 1997 | A |
5601088 | Swanson et al. | Feb 1997 | A |
5605157 | Panescu et al. | Feb 1997 | A |
5609157 | Panescu et al. | Mar 1997 | A |
5630425 | Panescu et al. | May 1997 | A |
5647870 | Kordis et al. | Jul 1997 | A |
5657755 | Desai | Aug 1997 | A |
5687737 | Branham et al. | Nov 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5702386 | Stern et al. | Dec 1997 | A |
5711305 | Swanson et al. | Jan 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5722403 | McGee et al. | Mar 1998 | A |
5722416 | Swanson et al. | Mar 1998 | A |
5732698 | Swanson et al. | Mar 1998 | A |
5735846 | Panescu et al. | Apr 1998 | A |
5740808 | Panescu et al. | Apr 1998 | A |
5752518 | McGee et al. | May 1998 | A |
5755715 | Stern et al. | May 1998 | A |
5769847 | Panescu et al. | Jun 1998 | A |
5792064 | Panescu et al. | Aug 1998 | A |
5795303 | Swanson et al. | Aug 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5797905 | Fleischman et al. | Aug 1998 | A |
5810802 | Panescu et al. | Sep 1998 | A |
5830213 | Panescu et al. | Nov 1998 | A |
5833621 | Panescu et al. | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5840076 | Swanson et al. | Nov 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5846239 | Swanson et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5853409 | Swanson et al. | Dec 1998 | A |
5853411 | Whayne et al. | Dec 1998 | A |
5868680 | Steiner et al. | Feb 1999 | A |
5868736 | Swanson et al. | Feb 1999 | A |
5871483 | Jackson et al. | Feb 1999 | A |
5876336 | Swanson et al. | Mar 1999 | A |
5879348 | Owens et al. | Mar 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5904680 | Kordis et al. | May 1999 | A |
5906614 | Stern et al. | May 1999 | A |
5908445 | Whayne et al. | Jun 1999 | A |
5911739 | Kordis et al. | Jun 1999 | A |
5916163 | Panescu et al. | Jun 1999 | A |
5925038 | Panescu et al. | Jul 1999 | A |
5928228 | Kordis et al. | Jul 1999 | A |
5935079 | Swanson et al. | Aug 1999 | A |
5941251 | Panescu et al. | Aug 1999 | A |
5954661 | Greenspon et al. | Sep 1999 | A |
5954662 | Swanson et al. | Sep 1999 | A |
5961513 | Swanson et al. | Oct 1999 | A |
5968040 | Swanson et al. | Oct 1999 | A |
6014581 | Whayne et al. | Jan 2000 | A |
6014590 | Whayne et al. | Jan 2000 | A |
6022346 | Panescu et al. | Feb 2000 | A |
6030379 | Panescu et al. | Feb 2000 | A |
6030382 | Fleischman et al. | Feb 2000 | A |
6035226 | Panescu | Mar 2000 | A |
6047218 | Whayne et al. | Apr 2000 | A |
6049732 | Panescu et al. | Apr 2000 | A |
6053912 | Panescu et al. | Apr 2000 | A |
6056745 | Panescu et al. | May 2000 | A |
6070094 | Swanson et al. | May 2000 | A |
6071278 | Panescu et al. | Jun 2000 | A |
6076012 | Swanson et al. | Jun 2000 | A |
6086532 | Panescu et al. | Jul 2000 | A |
6095150 | Panescu et al. | Aug 2000 | A |
6101409 | Swanson et al. | Aug 2000 | A |
6101410 | Panescu et al. | Aug 2000 | A |
6106460 | Panescu et al. | Aug 2000 | A |
6106522 | Fleischman et al. | Aug 2000 | A |
6113591 | Whayne et al. | Sep 2000 | A |
6115626 | Whayne et al. | Sep 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6129669 | Panescu et al. | Oct 2000 | A |
6129724 | Fleischman et al. | Oct 2000 | A |
6162184 | Swanson et al. | Dec 2000 | A |
6165169 | Panescu et al. | Dec 2000 | A |
6171306 | Swanson et al. | Jan 2001 | B1 |
6179835 | Panescu et al. | Jan 2001 | B1 |
6183468 | Swanson et al. | Feb 2001 | B1 |
6188924 | Swanson et al. | Feb 2001 | B1 |
6192266 | Dupree et al. | Feb 2001 | B1 |
6197021 | Panescu et al. | Mar 2001 | B1 |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6216043 | Swanson et al. | Apr 2001 | B1 |
6221013 | Panescu et al. | Apr 2001 | B1 |
6226542 | Reisfeld | May 2001 | B1 |
6233491 | Kordis et al. | May 2001 | B1 |
6245061 | Panescu et al. | Jun 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6256540 | Panescu et al. | Jul 2001 | B1 |
6289239 | Panescu et al. | Sep 2001 | B1 |
6293943 | Panescu et al. | Sep 2001 | B1 |
6301496 | Reisfeld | Oct 2001 | B1 |
6330473 | Swanson et al. | Dec 2001 | B1 |
6353751 | Swanson et al. | Mar 2002 | B1 |
6370435 | Panescu et al. | Apr 2002 | B2 |
6389311 | Whayne et al. | May 2002 | B1 |
6391024 | Sun et al. | May 2002 | B1 |
6428536 | Panescu et al. | Aug 2002 | B2 |
6456864 | Swanson et al. | Sep 2002 | B1 |
6456867 | Reisfeld | Sep 2002 | B2 |
6471699 | Fleischman et al. | Oct 2002 | B1 |
6487441 | Swanson et al. | Nov 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6490468 | Panescu et al. | Dec 2002 | B2 |
6494880 | Swanson et al. | Dec 2002 | B1 |
6500172 | Panescu et al. | Dec 2002 | B1 |
6508765 | Suorsa et al. | Jan 2003 | B2 |
6516807 | Panescu et al. | Feb 2003 | B1 |
6522913 | Swanson et al. | Feb 2003 | B2 |
6542773 | Dupree et al. | Apr 2003 | B2 |
6556695 | Packer et al. | Apr 2003 | B1 |
6565511 | Panescu et al. | May 2003 | B2 |
6569160 | Goldin et al. | May 2003 | B1 |
6597955 | Panescu et al. | Jul 2003 | B2 |
6615073 | Panescu et al. | Sep 2003 | B1 |
6625482 | Panescu et al. | Sep 2003 | B1 |
6647281 | Morency | Nov 2003 | B2 |
6652513 | Panescu et al. | Nov 2003 | B2 |
6658279 | Swanson et al. | Dec 2003 | B2 |
6668198 | Swanson et al. | Dec 2003 | B2 |
6735465 | Panescu | May 2004 | B2 |
6736811 | Panescu et al. | May 2004 | B2 |
6745076 | Wohlgemuth et al. | Jun 2004 | B2 |
6746401 | Panescu | Jun 2004 | B2 |
6788969 | Dupree et al. | Sep 2004 | B2 |
6790206 | Panescu | Sep 2004 | B2 |
6824515 | Suorsa et al. | Nov 2004 | B2 |
6895267 | Panescu et al. | May 2005 | B2 |
7194294 | Panescu et al. | Mar 2007 | B2 |
7364546 | Panescu et al. | Apr 2008 | B2 |
7505810 | Harlev et al. | Mar 2009 | B2 |
7515954 | Harlev et al. | Apr 2009 | B2 |
7565208 | Harris et al. | Jul 2009 | B2 |
7582084 | Swanson et al. | Sep 2009 | B2 |
7676264 | Pillai et al. | Mar 2010 | B1 |
7699829 | Harris et al. | Apr 2010 | B2 |
7729752 | Harlev et al. | Jun 2010 | B2 |
7774051 | Voth | Aug 2010 | B2 |
7794404 | Gutfinger et al. | Sep 2010 | B1 |
7869854 | Shachar et al. | Jan 2011 | B2 |
7925349 | Wong et al. | Apr 2011 | B1 |
7930018 | Harlev et al. | Apr 2011 | B2 |
7937136 | Harlev et al. | May 2011 | B2 |
7945326 | Wong et al. | May 2011 | B1 |
7946995 | Koh et al. | May 2011 | B1 |
7953475 | Harlev et al. | May 2011 | B2 |
7957791 | Harlev et al. | Jun 2011 | B2 |
7957792 | Harlev et al. | Jun 2011 | B2 |
7957813 | Persson et al. | Jun 2011 | B1 |
8010196 | Wong et al. | Aug 2011 | B1 |
8019419 | Panescu et al. | Sep 2011 | B1 |
8032218 | Wong et al. | Oct 2011 | B2 |
8038625 | Afonso et al. | Oct 2011 | B2 |
8065005 | Wong et al. | Nov 2011 | B1 |
8103327 | Harlev et al. | Jan 2012 | B2 |
8103338 | Harlev et al. | Jan 2012 | B2 |
8128617 | Bencini et al. | Mar 2012 | B2 |
8137343 | Harlev et al. | Mar 2012 | B2 |
8165666 | Briggs et al. | Apr 2012 | B1 |
8167876 | Harlev et al. | May 2012 | B2 |
8175680 | Panescu | May 2012 | B2 |
8202224 | Gutfinger et al. | Jun 2012 | B2 |
8208999 | Wenzel et al. | Jun 2012 | B2 |
8280511 | Zhao et al. | Oct 2012 | B2 |
8306623 | Wong et al. | Nov 2012 | B2 |
8364253 | Voth | Jan 2013 | B2 |
8369922 | Paul et al. | Feb 2013 | B2 |
8386049 | Persson et al. | Feb 2013 | B2 |
8406866 | Deno et al. | Mar 2013 | B2 |
8414579 | Kim et al. | Apr 2013 | B2 |
8449535 | Deno et al. | May 2013 | B2 |
8504152 | Wenzel et al. | Aug 2013 | B2 |
8504153 | Wenzel et al. | Aug 2013 | B2 |
8554333 | Wu et al. | Oct 2013 | B2 |
8571647 | Harlev et al. | Oct 2013 | B2 |
8600497 | Yang et al. | Dec 2013 | B1 |
8712519 | Panescu et al. | Apr 2014 | B1 |
8830235 | Guskov et al. | Sep 2014 | B1 |
20010000791 | Suorsa et al. | May 2001 | A1 |
20010009976 | Panescu et al. | Jul 2001 | A1 |
20010018608 | Panescu et al. | Aug 2001 | A1 |
20010020126 | Swanson et al. | Sep 2001 | A1 |
20010025175 | Panescu et al. | Sep 2001 | A1 |
20010044585 | Dupree et al. | Nov 2001 | A1 |
20020058870 | Panescu et al. | May 2002 | A1 |
20020065465 | Panescu et al. | May 2002 | A1 |
20020099415 | Panescu et al. | Jul 2002 | A1 |
20020111548 | Swanson et al. | Aug 2002 | A1 |
20020115941 | Whayne et al. | Aug 2002 | A1 |
20020143250 | Panescu et al. | Oct 2002 | A1 |
20020161422 | Swanson et al. | Oct 2002 | A1 |
20020193790 | Fleischman et al. | Dec 2002 | A1 |
20020198520 | Coen et al. | Dec 2002 | A1 |
20030028118 | Dupree et al. | Feb 2003 | A1 |
20030055419 | Panescu et al. | Mar 2003 | A1 |
20030065322 | Panescu et al. | Apr 2003 | A1 |
20030078494 | Panescu et al. | Apr 2003 | A1 |
20030078509 | Panescu | Apr 2003 | A1 |
20030088244 | Swanson et al. | May 2003 | A1 |
20030093067 | Panescu | May 2003 | A1 |
20030093069 | Panescu et al. | May 2003 | A1 |
20030144655 | Panescu | Jul 2003 | A1 |
20030153907 | Suorsa et al. | Aug 2003 | A1 |
20030158477 | Panescu | Aug 2003 | A1 |
20030199863 | Swanson et al. | Oct 2003 | A1 |
20030208123 | Panescu | Nov 2003 | A1 |
20040015065 | Panescu et al. | Jan 2004 | A1 |
20040097803 | Panescu | May 2004 | A1 |
20040254437 | Hauck et al. | Dec 2004 | A1 |
20050177151 | Coen et al. | Aug 2005 | A1 |
20050197657 | Goth et al. | Sep 2005 | A1 |
20050215945 | Harris et al. | Sep 2005 | A1 |
20050245949 | Goth et al. | Nov 2005 | A1 |
20060030833 | Harris et al. | Feb 2006 | A1 |
20060064083 | Khalaj et al. | Mar 2006 | A1 |
20060089688 | Panescu | Apr 2006 | A1 |
20060135957 | Panescu | Jun 2006 | A1 |
20060184166 | Valle et al. | Aug 2006 | A1 |
20070055227 | Khalaj et al. | Mar 2007 | A1 |
20070073179 | Afonso et al. | Mar 2007 | A1 |
20070073286 | Panescu et al. | Mar 2007 | A1 |
20070156048 | Panescu et al. | Jul 2007 | A1 |
20070232949 | Saksena | Oct 2007 | A1 |
20070299351 | Harlev et al. | Dec 2007 | A1 |
20070299352 | Harlev et al. | Dec 2007 | A1 |
20070299353 | Harlev et al. | Dec 2007 | A1 |
20080190438 | Harlev et al. | Aug 2008 | A1 |
20080249424 | Harlev et al. | Oct 2008 | A1 |
20080262361 | Gutfinger et al. | Oct 2008 | A1 |
20090018597 | Wenzel et al. | Jan 2009 | A1 |
20090171274 | Harlev et al. | Jul 2009 | A1 |
20090171345 | Miller et al. | Jul 2009 | A1 |
20090177071 | Harlev et al. | Jul 2009 | A1 |
20090177072 | Harlev et al. | Jul 2009 | A1 |
20090253976 | Harlev et al. | Oct 2009 | A1 |
20090262109 | Markowitz et al. | Oct 2009 | A1 |
20090281439 | Harlev et al. | Nov 2009 | A1 |
20090287267 | Wenzel et al. | Nov 2009 | A1 |
20090299211 | Wenzel et al. | Dec 2009 | A1 |
20100004712 | Zhao et al. | Jan 2010 | A1 |
20100023085 | Wu et al. | Jan 2010 | A1 |
20100030294 | Wong et al. | Feb 2010 | A1 |
20100091834 | Cheung et al. | Apr 2010 | A1 |
20100094274 | Narayan et al. | Apr 2010 | A1 |
20100106009 | Harlev et al. | Apr 2010 | A1 |
20100106154 | Harlev et al. | Apr 2010 | A1 |
20100274150 | Harlev et al. | Oct 2010 | A1 |
20100286550 | Harlev et al. | Nov 2010 | A1 |
20100286551 | Harlev et al. | Nov 2010 | A1 |
20100305433 | Harlev et al. | Dec 2010 | A1 |
20100324414 | Harlev et al. | Dec 2010 | A1 |
20110028821 | Bojovic et al. | Feb 2011 | A1 |
20110105928 | Bojovic et al. | May 2011 | A1 |
20110112413 | Panescu et al. | May 2011 | A1 |
20110112414 | Panescu et al. | May 2011 | A1 |
20110112415 | Bojovic et al. | May 2011 | A1 |
20110125150 | Deno et al. | May 2011 | A1 |
20110160574 | Harlev et al. | Jun 2011 | A1 |
20110166472 | Björling et al. | Jul 2011 | A1 |
20110184300 | Shvilkin et al. | Jul 2011 | A1 |
20110190625 | Harlev et al. | Aug 2011 | A1 |
20110202113 | Persson et al. | Aug 2011 | A1 |
20110275949 | Harlev et al. | Nov 2011 | A1 |
20110282186 | Harlev et al. | Nov 2011 | A1 |
20110282187 | Harlev et al. | Nov 2011 | A1 |
20110306896 | Altmann | Dec 2011 | A1 |
20120004533 | Peng et al. | Jan 2012 | A1 |
20120053470 | Wong et al. | Mar 2012 | A1 |
20120078077 | Harlev et al. | Mar 2012 | A1 |
20120130267 | Harlev et al. | May 2012 | A1 |
20120143030 | Harlev et al. | Jun 2012 | A1 |
20120184858 | Harlev et al. | Jul 2012 | A1 |
20120184863 | Harlev et al. | Jul 2012 | A1 |
20120184864 | Harlev et al. | Jul 2012 | A1 |
20120184865 | Harlev et al. | Jul 2012 | A1 |
20120245481 | Blanco et al. | Sep 2012 | A1 |
20120253161 | Harlev et al. | Oct 2012 | A1 |
20120265054 | Olson | Oct 2012 | A1 |
20120277574 | Panescu | Nov 2012 | A1 |
20120283587 | Gosh et al. | Nov 2012 | A1 |
20130035576 | O'Grady et al. | Feb 2013 | A1 |
20130060245 | Grunewald et al. | Mar 2013 | A1 |
20130096447 | Dhawan et al. | Apr 2013 | A1 |
20130123775 | Grunewald et al. | May 2013 | A1 |
20130137999 | Wenzel et al. | May 2013 | A1 |
20130138003 | Kaski | May 2013 | A1 |
20130173222 | Voth | Jul 2013 | A1 |
20130204124 | Duindam et al. | Aug 2013 | A1 |
20130226016 | Narayan et al. | Aug 2013 | A1 |
20130274582 | Afonso et al. | Oct 2013 | A1 |
20130303892 | Zhao et al. | Nov 2013 | A1 |
20130303945 | Blumenkranz et al. | Nov 2013 | A1 |
20140100440 | Cheline et al. | Apr 2014 | A1 |
20140278321 | Zhang et al. | Sep 2014 | A1 |
20140310016 | Kenney et al. | Oct 2014 | A1 |
20150016749 | Chen et al. | Jan 2015 | A1 |
20150065836 | Thakur | Mar 2015 | A1 |
20150196214 | Shuros et al. | Jul 2015 | A1 |
20150196215 | Laughner et al. | Jul 2015 | A1 |
20150196216 | Laughner et al. | Jul 2015 | A1 |
20150250399 | Laughner et al. | Sep 2015 | A1 |
Number | Date | Country |
---|---|---|
1190671 | Mar 2002 | EP |
2258263 | Aug 2012 | EP |
2007035306 | Mar 2007 | WO |
2007137045 | Nov 2007 | WO |
2007146864 | Dec 2007 | WO |
2008097767 | Aug 2008 | WO |
2009085108 | Jul 2009 | WO |
2009123819 | Oct 2009 | WO |
2010051183 | May 2010 | WO |
2010058372 | May 2010 | WO |
2010123637 | Oct 2010 | WO |
2010129095 | Nov 2010 | WO |
2011021948 | Feb 2011 | WO |
2011142931 | Nov 2011 | WO |
2011142932 | Nov 2011 | WO |
2012092016 | Jul 2012 | WO |
2012097059 | Jul 2012 | WO |
2012097067 | Jul 2012 | WO |
2012151301 | Nov 2012 | WO |
2015066322 | May 2015 | WO |
2015106196 | Jul 2015 | WO |
2015106201 | Jul 2015 | WO |
2015106254 | Jul 2015 | WO |
2015134276 | Sep 2015 | WO |
Entry |
---|
International Preliminary Report on Patentability issued in PCT/US2014/063148, mailed May 12, 2016, 9 pages. |
International Preliminary Report on Patentability issued in PCT/US2015/011013 mailed Jul. 28, 2016, 8 pages. |
International Preliminary Report on Patentability issued in PCT/US2015/011025, mailed Jul. 28, 2016, 6 pages. |
International Preliminary Report on Patentabiiity issued in PCT/US2015/011170 mailed Jul. 28, 2016, 7 pages. |
Faes, L., et. al. Principal Component Analysis and Cluster Analysis for Measuring the Local Organization of Human Atrial Fibrillation. Med. Biol. Eng. Comput., 39(6): 656-663, 2001. |
International Search Report and Written Opinion issued in PCT/US2015/018016, mailed May 20, 2015, 13 pages. |
Mats, R. J., et. al. A Two-Stage Mechanism for Registration and Ciassification of ECG Using Gaussian Mixture Model. Pattern Recognition, 42(11): 2979-2988, 2009. |
Blanchard, Susan M., et al., “Four Algorithms for Activation Detection from Unipolar Epicardial Electrograms”, IEEE Transactions on Biomedical Engineering, 36(2):256-261, Feb. 1, 1989. |
Blanchard, Susan M., et al., “Interpolating Unipolar Epicardial Potentials from Electrodes Separated by Increasing Distances”, PACE and Clinical Electrophysiology, 12(12):1938-1955, Dec. 1, 1989. |
Chen I-Ching, et al. “Radiofrequency Ablation Therapy in Concealed Left Free Wall Accessory Pathway With Decremental Conduction,” The Cardiopulmonary and Critical Care Journal. CHEST. New York City, New York. pp. 107(1 ):40-45, Jan. 1995. |
Corinna B. Brunckorst, et al. “Identification of the Ventricular Tachycardia Isthmus After lnfarction by Pace Mapping,” Circulation Journal of the American Heart Assoication. Volume Circulation, American Heart Association. Dallas, Texas, 110:652-659, Aug. 2, 2004. |
Deepak Bhakta, et al. “Principles of Electroanatornic Mapping,” Indian Pacing and Electrophysiology Journal. Krannert Institute of Cardiology. Indianapolis, Indiana, 8(1 ):32-50, 2008. |
Etienne M. Aliot, et al. “EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias,” European Society of Cardiology. The European Heart Rhythm Association, 11:771-817, 2009. |
Feifan Ouyang, et al. “Electroanatornic Substrate of Idiopathic Left Ventricular Tachycardia: Unidirectional Block and Macroreentry Wthin the Purkinje Network,” Circulation Journal of the American Heart Association. American Heart Associatio. Dallas, Texas, 105(10):462-469, 2002. |
He, Ye H., “An interactive graphical system for automated mapping and display of cardiac rhythms”, Journal of Electrocardiology, vol. 32, No. 3, Jul. 1, 1999, pp. 225-241. |
Hong Cao, et al. “FEM Analysis of Predicting Electrode-Myocardium Contact From RF Cardiac Catheter Ablation System Impedance,” IEEE Transactions on Biomedical Engineering. IEEE Engineering in Medicine and Biology Society. Madison, Wisconsin. 49(6):520-526, Jun. 2002. |
International Search Report and Written Opinion issued in PCT/US2014/063148, mailed Feb. 4, 2015, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2015/011013, mailed Sep. 4, 2015, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2015/011025, mailed Apr. 2, 2015, 8 pages. |
International Search Report and Written Opinion issued in PCT/US2015/011170, mailed Apr. 28, 2015, 9 pages. |
International Search Report and Written Opinion issued in PCT/US2015/017775, mailed May 26, 2015, 11 pages. |
Jang-Zern Tsai, et al. “Dependence of Apparent Resistance of Four-Electrode Probes on Insertion Depth,” IEEE Transactions on Biomedical Engineering. IEEE Engineering in Medicine and Biology Society. Madison, Wisconsin, 47(1):41-48, Jan. 2000. |
Jang-Zern Tsai, et al. “Error Analysis of Tissue Resistivity Measurement. IEEE Transactions on Biomedical Engineering,” IEEE Engineering in Medicine and Biology Society. Madison, Wisconsin, 49(5):484-494, May 2002. |
Jason Ng, et al. “Undertanding and Interpreting Dominant Fequeny Analysis of AF Electrogams,” J Cardiovasc Electrophysiol. Blackwell. Chicago, Illinois. 18(6):680-685, 2007. |
Ji-Qiang Hu, et al. “The Characteristics of Verapamil-sensitive Idiopathic left Ventricular Tachycardia combined with a left accessory pathway and the effect of radiofrequency catheter ablation,” Clinical Research Electrophysiology and Ablation. The European Society of Cardiology, Beijing, China. pp. 704-708, Jun. 30, 2011. |
Joseph B. Morton, et al. “Sensitivity and Specificity of Concealed Entrainment for the Identification of Critical Isthmus in the Atrium: Relationship to Rate, Anatomic Location and Antidromic Penetration,” Journal of the American College of Cardiology, Elsevier Science Inc. Melbourne, Australia. 39(5):896-906. Mar. 6, 2002. |
Ken Okumura, et al. “Pathophysiology and Natural History Ventricular Tachycardia. Demonstration of the Presence of Slow Conduction During Sustained Ventricular Tachycardia in Man: Use of Transient Entrainment of the Tachycardia,” Department of Medicine, Case Western Reserve University/University Hospitals of Cleveland, Ohio and the University of Alabama at Birmingham; 75(2):369-378, Feb. 1987. |
Koonlawee Nademanee, et al. “How to perform Electrogram-guided Atrial Fibrillation Ablation,” The Pacific Rim Electrophysiology Research Institute. Heart Rhythm Society. Inglewood, California, 3(8):981-984, Aug. 2006. |
Koonlawee Nademanee, et al. A New Approach for Catheter Ablation of Atrial Fibrillation: Mapping of the Electrophysiologic Substrate. Journal of the American College of Cardiology. Jun. 2, 2004. 43(11 ):2044-2053. Elsevier Inc. Inglewood, California; and Bangkok, Thailand. |
Minglong Chen, et al. “Non-contact mapping and linear ablation of the left posterior fascicle during sinus rhythm in the treatment of idiopathic left ventricular tachycardia,” European Society of Cardiology. vol. 7: pp. 138-144, Elsevier Ltd. China, 2005. |
Nademanee K, et al. “Catheter Ablation of Atrial Fibrillation guided by complex Fractionated Atrial Electrogram Mapping of Atrial Fibrillation Substrate,” Pacific Rim Eltrophysiology Research Institute. Elsevier Ltd. Los Angeles, California. 55(3):1-12, May 2010. |
Prashanthan Sanders, et al. Spectral Analysis Identifies Sites of High-Frequency Activity Maintaining Atrial Fibrillation in Humans. Circulation Journal of the American Heart Association. The American Heart Association, Inc. Dallas, Texas, 112:789-797, Aug. 9, 2005. |
Quan Ni, et al. “A Novel Interpolation Method of Electric Potential Fields in the Heart during Excitation,” Annals of Biomedical Engineering. Biomedical Engineering Society. Salt Lake City, Utah. vol. 26:597-607, 1998. |
Shiro Nakahara, et al. “Characterization of the Arrhythmogenic Substrate in Ischemic and Nonischemic Cardiomyopathy. Implications for Catheter Ablation of Hemodynamically Unstable Ventricular Tachycardia,” Journal of the American College of Cardiology. Los Angeles, California, 55(21 ):2355-2365, May 25, 2010. |
Stevenson WG, et al. “Identifying sites for Catheter Ablation of Ventricular Tachycardia,” PubMed NCB I. MeSH Terms, Abstract, Jun. 1992. |
Takeshi Tsuchiya. et al. “Significance of Late Diastolic Potential Preceding Purkinje Potential in Verapamil-Sensitive Idiopathic Left Ventricular Tachycardia.” American Heart Association. Japan, pp. 2408-2413, May 11, 1999. |
William G. Stevenson, et al. “Identification of Reentry Circuit Sites During Catheter Mapping and Radiofrequency Ablation of Ventricular Tachycardia Late After Myocardial Infarction,” Circulation. American Heart Association. Los Angeles, California. 88(4)1 646-1670, Oct. 1993. |
William G. Stevenson, et al. “Recording Techniques of Clinical Electrophysiology,” J Cardiovasc Electrophysiol. Blackwell. Boston, Massachusetts. 16(9):1017-1022, 2005. |
William G. Stevenson, et al. Journal of the American College of Cardiology. Fractionated Endocardial Electrograms are Associated With Slow Conduction in Humans: Evidence From Pace-Mapping, Los Angeles, California, 13(2):369-376, Feb. 1989. |
Yilmaz, B., et. al. Usage of Spline Interpolation in Catheter-Based Cardiac Mapping. Turk. J. Elec. Eng. & Comp. Sci., 18(6):989-1002, 2010. |
International Preliminary Report on Patentability issued in PCT/US2015/017775 mailed Sep. 22, 2016, 7 pages. |
International Preliminary Report on Patentability issued in PCT/US2015/018016, mailed Sep. 22, 2016, 9 pages. |
Number | Date | Country | |
---|---|---|---|
20150257671 A1 | Sep 2015 | US |
Number | Date | Country | |
---|---|---|---|
61951266 | Mar 2014 | US |